Compare AHH & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHH | MNPR |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.8M | 531.6M |
| IPO Year | 2013 | 2019 |
| Metric | AHH | MNPR |
|---|---|---|
| Price | $6.77 | $69.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $8.13 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 1.1M | 186.6K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | ★ 12.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $452,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.68 | N/A |
| P/E Ratio | $35.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $21.00 |
| 52 Week High | $10.55 | $105.00 |
| Indicator | AHH | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 38.47 |
| Support Level | $6.90 | $64.25 |
| Resistance Level | $7.13 | $77.45 |
| Average True Range (ATR) | 0.15 | 5.24 |
| MACD | 0.03 | -1.31 |
| Stochastic Oscillator | 48.94 | 24.95 |
Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.